Goldman Sachs downgrades Apellis stock to Sell on Syfovre growth concerns

Published 26/09/2025, 10:56
Goldman Sachs downgrades Apellis stock to Sell on Syfovre growth concerns

Investing.com - Goldman Sachs downgraded Apellis Pharmaceuticals (NASDAQ:APLS) from Neutral to Sell and lowered its price target to $18.00, citing concerns about the growth trajectory of the company’s geographic atrophy treatment Syfovre. The stock, currently trading at $22.22, has already declined over 30% year-to-date, according to InvestingPro data, which shows the company maintains a solid current ratio of 3.77, indicating strong short-term liquidity.

The investment bank highlighted several risks to Syfovre’s outlook, including limited penetration of geographic atrophy therapies into the diagnosed population, which currently stands at approximately 10-15% according to Apellis and Astellas. Goldman Sachs also noted that physicians continue to debate the functional meaningfulness of reduction in geographic atrophy lesion area. Despite these concerns, InvestingPro data reveals the company achieved 20% revenue growth in the last twelve months, with analysts projecting 29% growth for the upcoming fiscal year.

Additional concerns include a superior risk-benefit perception associated with competitor drug Izervay based on key opinion leader discussions, and high patient attrition rates due to funding shortages in co-pay assistance programs. The firm mentioned that these constraints have worsened in recent weeks as a not-for-profit organization separated support programs for retinal and macular diseases.

Goldman Sachs now models peak sales of $1.1 billion for Syfovre in 2030, below the consensus estimate of $1.3 billion. The firm expressed optimism about the launch of Empaveli in rare kidney diseases C3G/IC-MPGN, citing superior data and broader labeling compared to competitor Fabhalta, but believes the current share price already reflects this opportunity. According to InvestingPro, analyst targets for APLS range from $19 to $60, with 9 analysts recently revising their earnings estimates upward. Subscribers can access the full Pro Research Report for comprehensive analysis of Apellis’s growth prospects and valuation metrics.

The downgrade also noted an absence of near-term catalysts in Apellis’ pipeline that could drive share price upside, with longer-term growth for Syfovre potentially emerging in the second half of 2026 and beyond through commercial developments such as pre-filled syringe presentation and AI-enabled technologies.

In other recent news, Apellis Pharmaceuticals Inc. announced its Q2 2025 earnings, which exceeded analysts’ expectations for earnings per share (EPS). The company reported an EPS of -$0.33, outperforming the anticipated -$0.48. However, the revenue figures did not meet projections, coming in at $178 million compared to the forecasted $186.76 million. Despite the shortfall in revenue, the unexpected EPS results and ongoing progress in product development have positively influenced investor sentiment. These recent developments highlight the company’s strategic focus and operational performance. Analysts and investors are closely monitoring Apellis Pharmaceuticals’ financial health and strategic initiatives. The earnings report has sparked renewed interest in the company’s future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.